Copyright © Inderes 2011 - present. All rights reserved.

Pharma Equity Group

0.144

 

DKK

 

+2.86 %

Less than 1K followers

PEG

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Compare
+2.86%
+4.35%
-24.21%
-19.33%
-39.75%
-56.89%
-26.15%
-80.47%
-99.45%

Pharma Equity Group develops new medicines for the local treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The company uses repositioning of existing drugs and brings drug candidates to a clinical phase III stage, after which it is handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the company.

Read more
Market cap
176.77M DKK
Turnover
37.5K DKK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Coverage
Disclaimer
Claus Thestrup
Claus Thestrup

CEO, Sweden

Latest research

Latest analysis report

Released: 28.10.2024

Financial calendar
16.4
2025

General meeting '25

15.5
2025

Interim report Q1'25

14.8
2025

Interim report Q2'25

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Pharma Equity Group – Opdatering på helåret 2024
Webcast

Pharma Equity Group – Opdatering på helåret 2024

Mød og stil spørgsmål til CEO Thomas K. Selsø fra Pharma Equity Group torsdag den 20. marts 2025 kl 13:00. Fokus for dette event vil årsregnskabet for 2024, samt pipeline opdatering på RNX-011(Perionitis) og RNX-051(tyktarmscancer). Derudover vil CEO Thomas K. Selsø give en opdatering på drøftelserne med potentielle partnere.

Pharma Equity Group
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.